BioSpace News Archive

ImmersiveTouch, announced today in conjunction with RSNA 2021 that it received Food and Drug Administration (FDA) 510(k) Clearance for its modular software package that allows users to import, visualize, and automatically segment medical images to create accurate 3-dimensional representations.

StatLab Medical Products (StatLab), a leading developer and manufacturer of diagnostic supplies and equipment for the anatomic pathology market, today announced the appointment of industry veteran Kim Kelderman to the StatLab Board of Directors.

Detect™, Inc., a Connecticut-based health technology company, announced today that its PCR-quality, at-home rapid molecular Detect™ Covid-19 Test recognizes the Omicron (B.1.1.529) SARS CoV-2 variant.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one oral presentation and three poster presentations at the 32nd International Symposium on ALS/MND taking place online from December 7 – December 10, 2021.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events.

Dr. Michael B. McDonnell hired as Chief Medical Officer, Dr. Jeffrey Sprouse as Director of Pipeline Development, Jamie Jarecki-Smith as Director of Clinical Operations and Dr. Nancy Raimondi as Director of Intellectual Property.

NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to evaluate NKT2152.

Twist Bioscience Corporation today announced that Steffen Hellmold, senior vice president, business development, data storage, will participate in the virtual SRC-SIA Webinar on the Decadal Plan for Semiconductors held on December 9, 2021 from 12:30pm to 2:00pm (EST).

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today the United States Food and Drug Administration’s (FDA’s) authorization to expand its Revitalize-1 pivotal clinical study (formerly known as REVITA-T2Di) sample size from 288 to 420.